Verona Pharma Plc ADR (NASDAQ:VRNA) price on Friday, March 21, rose 0.81% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $66.81.
A look at the stock’s price movement, the close in the last trading session was $66.27, moving within a range at $65.5 and $66.87. The beta value (5-Year monthly) was 0.393. Turning to its 52-week performance, $70.40 and $11.39 were the 52-week high and 52-week low respectively. Overall, VRNA moved 4.08% over the past month.
Verona Pharma Plc ADR’s market cap currently stands at around $5.65 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 41.55M for the company’s revenue for the quarter, with a low and high estimate of 33.5M and 53.2M respectively. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 243.69M, representing a 627.57% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VRNA is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 7 recommend VRNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VRNA’s current price about 2.22% and 10.91% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.52, while 7-day volatility ratio is 5.40% and 6.04% in the 30-day chart. Further, Verona Pharma Plc ADR (VRNA) has a beta value of 0.14, and an average true range (ATR) of 3.59. Analysts have given the company’s stock an average 52-week price target of $75, forecast between a low of $74 and high of $83. Looking at the price targets, the low is -10.76% off current price level while to achieve the yearly target high, price needs to move -24.23%. Nonetheless, investors will most likely welcome a -12.26% jump to $75 which is the analysts’ median price.
If we refocus on Verona Pharma Plc ADR (NASDAQ:VRNA), historical trading data shows that trading volumes averaged 1.25 over the past 10 days and 1.43 million over the past 3 months. The company’s latest data on shares outstanding shows there are 84.63 million shares.
The 12.31% of Verona Pharma Plc ADR’s shares are in the hands of company insiders while institutional holders own 69.57% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.0 million on 2025-02-28, giving us a short ratio of 5.86. The data shows that as of 2025-02-28 short interest in Verona Pharma Plc ADR (VRNA) stood at 1104.0 of shares outstanding, with shares short rising to 8.29 million registered in 2025-01-31. Current price change has pushed the stock 43.86% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VRNA stock continues to rise going into the next quarter.
